Personalised advanced therapies in parkinson’s disease: The role of non-motor symptoms profile

Valentina Leta, Haidar S. Dafsari, Anna Sauerbier, Vinod Metta, Nataliya Titova, Lars Timmermann, Keyoumars Ashkan, Michael Samuel, Eero Pekkonen, Per Odin, Angelo Antonini, Pablo Martinez-Martin, Miriam Parry, Daniel J. Van Wamelen, K. Ray Chaudhuri*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)


Device-aided therapies, including levodopa-carbidopa intestinal gel infusion, apomorphine subcutaneous infusion, and deep brain stimulation, are available in many countries for the management of the advanced stage of Parkinson’s disease (PD). Currently, selection of device-aided therapies is mainly focused on patients’ motor profile while non-motor symptoms play a role limited to being regarded as possible exclusion criteria in the decision-making process for the delivery and sustenance of a successful treatment. Differential beneficial effects on specific non-motor symptoms of the currently available device-aided therapies for PD are emerging and these could hold relevant clinical implications. In this viewpoint, we suggest that specific non-motor symptoms could be used as an additional anchor to motor symptoms and not merely as exclusion criteria to deliver bespoke and patient-specific personalised therapy for advanced PD.

Original languageEnglish
Article number773
JournalJournal of Personalized Medicine
Issue number8
Publication statusPublished - Aug 2021


  • Apomorphine
  • Deep brain stimulation
  • Device-aided therapies
  • Levodopa-carbidopa intestinal gel
  • Non-motor symptoms
  • Parkinson’s disease
  • Personalised medicine


Dive into the research topics of 'Personalised advanced therapies in parkinson’s disease: The role of non-motor symptoms profile'. Together they form a unique fingerprint.

Cite this